The present invention relates to nanoparticles complexed with therapeutic agents configured for treating cardiovascular related disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising synthetic HDL (sHDL) nanoparticles carrying therapeutic agents configured for treating cardiovascular related disorders, methods for synthesizing such sHDL nanoparticles, as well as systems and methods utilizing such sHDL nanoparticles (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutic agents, imaging agents, and/or targeting agents (e.g., in cardiovascular disease diagnosis and/or therapy, etc.))).

The peptide inhibitor of PSD-95, Tat-NR2B9c, is cleaved by the serum protease, plasmin, inducible by thrombolytic agents. Conversely, Tat-NR2B9c has no detrimental effect on the activity of a thrombolytic agent. Inactivation of Tat-NR2B9c by thrombolytic agents can be reduced or avoided by several approaches including spacing the administration of the respective agents to avoid substantial overlap in plasma residence between Tat-NR2B9c and plasmin, using mechanical instead of thrombolytic reperfusion or using active agent that inhibits PSD-95 not subject to cleavage by plasmin, e.g., D-amino acid variants of Tat-NR2B9c.

The peptide inhibitor of PSD-95, Tat-NR2B9c, is cleaved by the serum protease, plasmin, inducible by thrombolytic agents. Conversely, Tat-NR2B9c has no detrimental effect on the activity of a thrombolytic agent. Inactivation of Tat-NR2B9c by thrombolytic agents can be reduced or avoided by several approaches including spacing the administration of the respective agents to avoid substantial overlap in plasma residence between Tat-NR2B9c and plasmin, using mechanical instead of thrombolytic reperfusion or using active agent that inhibits PSD-95 not subject to cleavage by plasmin, e.g., D-amino acid variants of Tat-NR2B9c.

The present invention provides methods and combinations for reducing the infarct volume in a tissue of a subject undergoing ischemia or at risk of developing ischemia.

The present invention provides methods and combinations for reducing the infarct volume in a tissue of a subject undergoing ischemia or at risk of developing ischemia.

The present invention provides methods and combinations for reducing the infarct volume in a tissue of a subject undergoing ischemia or at risk of developing ischemia.

A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle or microparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle or microparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety.

A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle or microparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle or microparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety.

The present invention provides a method and drug for preventing and treating Alzheimer disease. The method includes: administering a therapeutically effective amount of a component of a plasminogen activation pathway to a subject. The present invention also provides a drug, pharmaceutical composition, product, and kit containing the component of the plasminogen activation pathway.

Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorders.